172 related articles for article (PubMed ID: 17385098)
1. Brain metastases in patients receiving trastuzumab for breast cancer.
Errante D; Bernardi D; Bianco A; Salvagno L
Neurol Sci; 2007 Mar; 28(1):52-3. PubMed ID: 17385098
[No Abstract] [Full Text] [Related]
2. Brain metastases in patients receiving trastuzumab for breast cancer.
Salmaggi A; Silvani A; Boiardi A
Neurol Sci; 2007 Mar; 28(1):1. PubMed ID: 17385088
[No Abstract] [Full Text] [Related]
3. Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer?
Abrey LE
Nat Clin Pract Neurol; 2006 Jun; 2(6):302-3. PubMed ID: 16932571
[No Abstract] [Full Text] [Related]
4. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
Lai R; Dang CT; Malkin MG; Abrey LE
Cancer; 2004 Aug; 101(4):810-6. PubMed ID: 15305414
[TBL] [Abstract][Full Text] [Related]
5. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.
Montemurro F; Aglietta M
Cancer; 2005 Mar; 103(6):1314-5; author reply 1315. PubMed ID: 15674855
[No Abstract] [Full Text] [Related]
6. Comment on: incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Errante D; Bernardi D; Bianco A; Salvagno L
Acta Oncol; 2007; 46(4):565-6. PubMed ID: 17497328
[No Abstract] [Full Text] [Related]
7. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab.
Montagna E; Cancello G; D'Agostino D; Lauria R; Forestieri V; Esposito A; Silvestro L; Accurso A; De Placido S; De Laurentiis M
Cancer Chemother Pharmacol; 2009 Jan; 63(2):275-80. PubMed ID: 18379783
[TBL] [Abstract][Full Text] [Related]
8. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab.
Yau T; Swanton C; Chua S; Sue A; Walsh G; Rostom A; Johnston SR; O'Brien ME; Smith IE
Acta Oncol; 2006; 45(2):196-201. PubMed ID: 16546866
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system metastases in breast cancer patients administered trastuzumab.
Duchnowska R; Szczylik C
Cancer Treat Rev; 2005 Jun; 31(4):312-8. PubMed ID: 15979804
[TBL] [Abstract][Full Text] [Related]
10. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
11. Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.
Altundag K; Altundag O; Atik MA; Morandi P; Gunduz M
Breast; 2005 Oct; 14(5):425. PubMed ID: 16216749
[No Abstract] [Full Text] [Related]
12. Treatment strategy of the HER 2 positive breast cancer with CNS metastases.
Belohorska B; Svec J; Vertakova-Krakovska B; Tkacova M
Bratisl Lek Listy; 2009; 110(5):324. PubMed ID: 19507673
[No Abstract] [Full Text] [Related]
13. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
14. Survival after brain metastases from breast cancer in the trastuzumab era.
Kirsch DG; Ledezma CJ; Mathews CS; Bhan AK; Ancukiewicz M; Hochberg FH; Loeffler JS
J Clin Oncol; 2005 Mar; 23(9):2114-6; author reply 2116-7. PubMed ID: 15774813
[No Abstract] [Full Text] [Related]
15. [Metastatic involvement of the central nervous system in breast cancer: role of herceptin].
Ocaña Fernández A; Navarro Martín M; Cruz Hernández JJ
Rev Clin Esp; 2005 Nov; 205(11):553-5. PubMed ID: 16324528
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab in CNS progressive metastatic breast cancer.
Tosoni A; Franceschi E; Esposti RD; Brandes AA
Future Oncol; 2007 Aug; 3(4):367-9. PubMed ID: 17661709
[No Abstract] [Full Text] [Related]
17. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
18. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier.
Stemmler HJ; Schmitt M; Willems A; Bernhard H; Harbeck N; Heinemann V
Anticancer Drugs; 2007 Jan; 18(1):23-8. PubMed ID: 17159499
[TBL] [Abstract][Full Text] [Related]
19. [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].
Hurkens KP; Hupperets PS; Creemers GJ; Erdkamp FL; van de Vijver KK; Tjan-Heijnen VC
Ned Tijdschr Geneeskd; 2008 Dec; 152(50):2701-6. PubMed ID: 19192581
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.
Montemurro F; Donadio M; Clavarezza M; Redana S; Jacomuzzi ME; Valabrega G; Danese S; Vietti-Ramus G; Durando A; Venturini M; Aglietta M
Oncologist; 2006 Apr; 11(4):318-24. PubMed ID: 16614227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
